



03CD  
Case Docket No. GENENT.0834  
Date: October 24, 2001

PATENT  
TECHNICAL CENTER 1600/2900

DEC 04 2001

RECEIVED  
# 5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Pennica et al.  
Appl. No. : 09/901,812  
Filed : July 10, 2001  
For : METHODS FOR  
ENHANCING THE  
EFFICACY OF CANCER  
THERAPY  
Examiner : Unknown  
Group Art Unit : 1645

I hereby certify that this correspondence and all  
marked attachments are being deposited with the  
United States Postal Service as first class mail in  
an envelope addressed to: Assistant Commissioner  
for Patents, Washington, D.C. 20231, on

October 24, 2001  
(Date)

  
Ginger R. Dreger, Reg. No. 33,055


TRANSMITTAL LETTER

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231  
ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with 302 references.
- (X) The Commissioner is hereby authorized to charge any additional fees, which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

  
Ginger R. Dreger  
Registration No. 33,055  
Attorney of Record

GENENT.083A



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

DEC 04 2001

RECEIVED

Applicant : Pennica et al. ) Group Art Unit 1645  
App. No. : 09/901,812 )  
Filed : July 10, 2001 )  
For : METHODS FOR )  
ENHANCING THE )  
EFFICACY OF CANCER )  
THERAPY )  
Examiner : Unknown

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 listing references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Oct 06, 24, 2001

By: Ginger R. Dreger

Ginger R. Dreger  
Registration No. 33,055  
Attorney of Record  
620 Newport Center Drive  
Sixteenth Floor  
Newport Beach, CA 92660  
(415) 954-4114

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
GENENT.83AAPPLICATION NO.  
09/901,812INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT  
Pennica et alFILING DATE  
July 10, 2001GROUP  
1645

(USE SEVERAL SHEETS IF NECESSARY)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1.	3,773,919	11.20.73	Boswell et al.			
	2.	4,179,337	12.18.79	Davis et al.			
	3.	4,275,149	6.23.81	Litman et al			
	4.	4,399,216	8.16.83	Axel et al.			
	5.	4,485,045	11.27.84	Regen			
	6.	4,496,689	1.20.85	Mitra			
	7.	4,544,545	10.1.85	Ryan et al.			
	8.	4,640,835	2.3.87	Shimizu et al.			
	9.	4,657,760	4.14.87	Kung et al.			
	10.	4,670,417	6.2.87	Iwasaki et al.			
	11.	4,676,980	6.30.87	Segal et al.			
	12.	4,736,866	4.12.88	Leder et al.			
	13.	4,791,192	12.13.88	Nakagawa et al.			
	14.	4,816,567	3.28.89	Cabilly et al.			
	15.	4,870,009	9.26.89	Evans et al.			
	16.	4,873,191	10.10.89	Wagner et al.			
	17.	4,943,529	7.24.90	Van Den Berg et al.			
	18.	4,975,278	12.4.90	Senter et al.			
	19.	5,010,182	4.23.91	Brake et al.			
	20.	5,013,556	5.7.91	Woodle et al.			
	21.	5,122,469	6.16.92	Mather et al.			
	22.	5,206,344	4.27.93	Katre et al.			
	23.	5,225,212	7.6.93	Martin et al.			
	24.	5,428,130	6.27.95	Capon et al.			
	25.	5,545,806	8.13.96	Lonberg et al.			
	26.	5,545,807	8.13.96	Surani et al.			

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
GENENT.83AAPPLICATION NO.  
09/901,812INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT  
Pennica et alFILING DATE  
July 10, 2001GROUP  
1645

USE SEVERAL SHEETS IF NECESSARY)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	27.	5,569,825	10.29.96	Lonberg et al.			
	28.	5,625,126	4.29.97	Lonberg et al.			
	29.	5,633,425	5.27.97	Lonberg et al.			
	30.	5,654,010	8.5.97	Johnson et al.			
	31.	5,661,016	8.26.97	Lonberg et al.			
	32.	6,187,819	2.13.01	Fisher et al.			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	33.	EP 03089	05.30.90	EP				
	34.	EP 117,058	08.29.84	EP				
	35.	EP 117,060	08.29.84	EP				
	36.	EP 139,383	05.02.85	EP				
	37.	EP 307,247	03.15.88	EP				
	38.	EP 36,776	09.30.81	EP				
	39.	EP 362,179	04.04.90	EP				
	40.	EP 394,538	10.31.90	EP				
	41.	EP 404,097	12.27.90	EP				
	42.	EP 616,812	09.28.94	EP				
	43.	EP 073,657	03.09.83	EP				
	44.	WO 81/01145	4.20.81	PCT				
	45.	WO 87/05330	9.11.87	PCT				
	46.	WO 84/03564	9.13.94	PCT				
	47.	WO 88/07378	10.6.88	PCT				
	48.	WO 89/05859	6.29.89	PCT				
	49.	WO 90/10048	9.7.90	PCT				
	50.	WO 90/13641	11.15.90	PCT				

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
GENENT.83AAPPLICATION NO.  
09/901,812INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Pennica et alFILING DATE  
July 10, 2001GROUP  
1645

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
/	51.	WO 90/13646	11.15.90	PCT				
/	52.	WO 91/00357	1.10.91	PCT				
/	53.	WO 91/00360	1.10.91	PCT				
/	54.	WO 91/04753	4.18.91	PCT				
/	55.	WO 93/11161	6.10.93	PCT				
/	56.	WO 93/17041	9.2.93	PCT				
/	57.	WO 93/18186	9.16.93	PCT				
/	58.	WO 94/11026	5.26.94	PCT				
/	59.	WO 96/07399	3.14.96	PCT				
/	60.	WO 96/27011	9.6.96	PCT				
/	61.	WO 96/40072	12.19.96	PCT				
/	62.	WO 97/03692	2.6.97	PCT				
/	63.	WO99/47162	9.23.99	PCT				
/	64.	WO 97/33551	9.18.97	PCT				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	65.	Alitalo and Schwab "Oncogene Amplification in Tumor Cells" <u>Adv. Cancer Res.</u> , 47:235-281 (1986)
	66.	Altschul et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs" <u>Nucleic Acids Res.</u> 25(17):3389-3402 (1997)
	67.	Anderson et al., "Direct Interactions of Coxsakievirus B3 with Immune Cells in the Splenic Compartment of Mice Susceptible or Resistant to Myocarditis" <u>Science</u> 256, 808-813 (1992)
	68.	Aquino et al., "Effect of the Combined Treatment with 5-Fluorouracil, $\gamma$ -Interferon or Folinic Acid on Carcinoembryonic Antigen Expression in Colon Cancer Cells" <u>Clinical Cancer Research</u> , 4(10): 2473-2481 (Oct. 1998)
	69.	Athauda et al., "Entrapment and Inhibition of Human Immunodeficiency Virus Proteinase by a $\alpha$ 2-Macroglobulin and Structural Changes in the Inhibitor" <u>J. Biochem.</u> , 113:742-746 (1993)
	70.	Ausubel et al., <u>Current Protocols of Molecular Biology</u> , John Wiley and Sons (1997)
	71.	Barker et al., "The Yin-Yang of TCF/ $\beta$ -Catenin Signaling" <u>Adv Cancer Res</u> 77:1-24 (2000)
	72.	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185her2 Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer" <u>J. Clin. Oncol.</u> , 14:737-744 (1996)

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
GENENT.83AAPPLICATION NO.  
09/901,812INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Pennica et alFILING DATE  
July 10, 2001GROUP  
1645EXAMINER  
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

73. Baselga et al., "HER2 Overexpression and Paclitaxel Sensitivity in Breast Cancer: Therapeutic implications" Oncology, 11 (3 Suppl 1):43-48 (1997)
74. Beach and Nurse, "High-frequency transformation of the fission yeast *Schizosaccharomyces pombe*" Nature, 290: 140 (1981)
75. Beal and Dervan et al., "Second Structural Motif for Recognition of DNA by Oligonucleotide-Directed Triple-Helix Formation" Science, 251:1360 (1991)
76. Beckmann, et al., "Molecular characterization of a family of ligands for eph-related tyrosine kinase receptors" EMBO J 13:3657 (1994)
77. Behrens, et al., "Functional Interaction of  $\beta$ -catenin with the transcription factor LEF-1" Nature 382:638-642 (1996)
78. Bergstein et al., "Isolation of Teo Novel WNT Genes, WNT14 AND wnt15, One of Which (WNT15) Is Closely linked to WNT3 on Human Chromosome 17q21" Genomics 46:450-458 (1997)
79. Bidyut Roy et al., "Synergistic Activation of Retinoic Acid (RA)-Responsive Genes and Induction of Embryonal Carcinoma Cell Differentiation by a RA Receptor  $\alpha$  (RAR $\alpha$ ), RAR $\beta$ -, or RAR $\gamma$ -Selective Ligand in Combination with a Retinoid X Receptor-Specific Ligand" Mol. Cell. Biol., 15(12):6481-7 (1995)
80. Bishop, Michael J., "Molecular Themes in Oncogenesis" Cell, 64:235-248 (1991)
81. Boerner et al., "Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes" J. Immunol., 147(1):86-95 (1991)
82. Bolivar et al., "Construction and characterization of new cloning vehicles" Gene, 2:95-113 (1977)
83. Boring et al., "Cancer Statistics, 1993" CA Cancer J. Clin., 43:7 (1993)
84. Bouillet et al., "Efficient Cloning of cDNA of Retinoic Acid-Responsive Genes in P19 Embryonal Carcinoma Cells and Characterization of a Novel Mouse Gene, Stra1 (Mouse LERK-2/Eplg2) Dev. Biol. 170:420-433 (1995)
85. Bouillet et al., "Developmental expression pattern of Stra6, a retinoic acid-responsive gene encoding a new type of membrane protein" Mechanisms of Development 63, 173-186 (1997)
86. Boven and Winograd, eds., The Nude Mouse in Oncology Research, CRC Press, Inc., 1991
87. Bradley, Allan, "Production and analysis of Chimaeric mice" in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E. J. Robertson, ed. (IRL, Oxford, 1987), 5:113-152
88. Braxton and Wells, "Incorporation of Stabilizing Ca<sup>2+</sup>-Binding Loop into Subtilisin BPN" Biochemistry, 31:7796-7801 (1992)
89. Brennan et al., "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments" Science 229:81 (1985)
90. Bui et al., "A novel human Wnt gene, WNT10B, maps to 12q13 and is expressed in human breast carcinomas" Oncogene 14:1249-1253 (1997)
91. C. Anthony, The Biochemistry of Methylotrophs, 269-295 (1982)
92. Caraglia et al., "5-Axa-2'-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor receptor on human epithelial cancer cells" Annals of Oncology, 5(3):269-76 (1994)
93. Caron et al., "Engineered Humanized Dimeric Forms of IgG Are More Effective Antibodies" J. Exp Med., 176: 1191-1195 (1992)
94. Carter et al., "Improved oligonucleotide site-directed mutagenesis using M13 vectors" Nucl. Acids Res., 13:4331 (1986)

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
GENENT.83AAPPLICATION NO.  
09/901,812INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Pennica et alFILING DATE  
July 10, 2001GROUP  
1645EXAMINER  
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

- |      |  |
|------|--|
| 95.  | Case et al., "Efficient Transformation of <i>Neurospora crassa</i> by Utilizing Hybrid Plasmid DNA" <u>Proc. Natl. Acad. Sci. USA</u> , 76:5259-5263 (1979)  |
| 96.  | Chang et al., "Phenotype expression in <i>E. coli</i> of a DNA sequence coding for mouse dihydrofolate reductase" <u>Nature</u> , 275:615 (1978)   |
| 97.  | Chazaud et al., "Restricted Expression of a Novel Retinoic Acid Responsive Gene During Limb Bud Dorsoventral Patterning and Endochondral Ossification" <u>Dev. Genet.</u> 19: 66-73 (1996)   |
| 98.  | Chevray and Nathans, "Protein interaction cloning in yeast: Identification of mammalian proteins that react with leucine zipper of Jun" <u>Proc. Natl. Acad. Sci. USA</u> , 89: 5789-5793 (1991)   |
| 99.  | Chien et al., "The two-hybrid system: A method to identify and clone genes for proteins that interact with a protein of interest" <u>Proc. Natl. Acad. Sci. USA</u> , 88:9578-9582 (1991)  |
| 100. | Chothia, Cyrus, "The Nature of the Accessible and Buried Surfaces in Proteins" <u>J. Mol. Biol.</u> , 150:1 (1976)   |
| 101. | Clark et al., "Molecular Cloning of the Human Proto-oncogene Wnt-5A and Mapping of the Gene (WNT5A) to Chromosome 3p14-p21" <u>Genomics</u> 18:249-260 (1993)  |
| 102. | Cleland, Jeffrey L., "Design and Production of Single Immunization Vaccines Using Polylactide Polyglycolide Microsphere Systems," in <u>Vaccine Design: The Subunit and Adjuvant Approach</u> , Powell and Newman, eds, (Plenum Press: New York, 1995), Chapter 18 pp. 439-462 |
| 103. | Clotman et al., "All-trans-Retinoic Acid Upregulates the Expression of COUP-TFI in Early-Somite Mouse Embryos Cultured In Vitro" <u>Neurotoxicol Teratol</u> 20:591-599 (1998)   |
| 104. | Cooney et al. "Site-Specific Oligonucleotide Binding Represses transcription of the Human c-myc Gene in Vitro", <u>Science</u> , 241: 456-459 (1988)   |
| 105. | Creighton, <u>Proteins: Structure and Molecular Properties</u> , W.H. Freeman & Co., San Francisco, (1983)   |
| 106. | Cunningham and Wells, "High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis" <u>Science</u> , 244: 1081-1085 (1989)  |
| 107. | David and Reisfeld., "Protein Iodination with Solid State Lactoperoxidase" <u>Biochemistry</u> , 13:1014 (1974)  |
| 108. | Davis, et al., "Ligands for EPH-Related Receptor Tyrosine Kinases That Require Membrane Attachment or Clustering for Activity" <u>Science</u> 266:816 (1994)   |
| 109. | deBoer et al., "The tac promoter: A functional hybrid derived from the trp and lac promoters" <u>Proc. Natl. Acad. Sci. USA</u> , 80:21-25 (1983)  |
| 110. | DeLeo et al., "Cell Surface Antigens of Chemically Induced Sarcomas of the Mouse" <u>J. Exp. Med.</u> , 146:720-730 (1977)   |
| 111. | Dennis et al., "A secreted Frizzled related protein, FrzA, selectively associates with Wnt-1 protein and regulates Wnt-1 signaling" <u>Journal of Cell Science</u> 112:3814-3820 (1999)  |
| 112. | Deutscher, Murray P. (Ed.), <u>Methods in Enzymology</u> , 182 (1990)  |
| 113. | Donehower et al., "Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability" <u>Genes Dev</u> 9:882-895 (1995)  |
| 114. | Drebin et al., "Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen" <u>PNAS USA</u> , 83:9129-9133 (1986)   |

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
GENENT.83AAPPLICATION NO.  
09/901,812INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Pennica et alFILING DATE  
July 10, 2001GROUP  
1645

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

- | EXAMINER<br>INITIAL | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)   |
|---------------------|--|
| 115                 | Drebin et al., "Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene" <u>Nature</u> 312(5994):545-8 (1984)                                       |
| 116                 | Duester, Gregg, "Families of retinoid dehydrogenases regulating vitamin A function Production of visual pigment and retinoic acid" <u>Eur J Biochem</u> 267:4315-4324 (2000)                     |
| 117                 | Easwaran et al., "Cross-regulation of $\beta$ -catenin-LEF/TCF and retinoid signaling pathways" <u>Curr. Biol.</u> 9:1415-1418 (1999)  |
| 118                 | Eberhard et al., "Alterations of Annexin Expression in Pathological Neuronal and Glial Reactions" <u>Am. J. Pathol.</u> 145:640-9 (1994)   |
| 119                 | Edge et al. "Deglycosylation of Glycoproteins by Trifluoromethanesulfonic Acid", <u>Anal. Biochem.</u> , 118:131-137 (1981)  |
| 120                 | Epstein et al. "Biological activity of liposome-encapsulated murine interferon $\gamma$ is mediated by a cell membrane receptor", <u>Proc. Natl. Acad. Sci. USA</u> , 82: 3688 (1985)            |
| 121                 | Evan et al., "Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product" <u>Molecular and Cellular Biology</u> , 5:3610-3616 (1985)                                     |
| 122                 | Fear et al., "Wnt-16a, a Novel Wnt-16 Isoform, Which Shows Differential Expression in Adult Human Tissues" <u>Biochem Biophys Res Commun</u> 278:814-820 (2000)                                  |
| 123                 | Field et al., "Purification of a RAS-Responsive Adenylyl Cyclase Complex from <i>Saccharomyces cerevisiae</i> by Use of an Epitope Addition Method" <u>Mol. Cell. Biol.</u> , 8:2159-2165 (1988) |
| 124                 | Fields and Song, "A novel genetic system to detect protein-protein interactions" <u>Nature</u> , 340:245-246 (1989)  |
| 125                 | Fishwild et al., "High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice" <u>Nature Biotechnology</u> 14, 845-51 (1996)                                  |
| 126                 | Fleer et al., "Stable Multicopy Vectors for High-Level Secretion of Recombinant Human Serum Albumin by <i>Kluyveromyces Yeasts</i> , <u>Bio/Technology</u> , 9:968-975 (1991)                    |
| 127                 | Fournier and Ozeki, "Structure and Organization of the Transfer Ribonucleic Acid Genes of <i>Escherichia coli</i> K-12", <u>Microbiol. Rev.</u> 49:379-397 (1985)                                |
| 128                 | Freund and Blair "Depression of Natural Killer Activity and Mitogen Responsiveness in Mice Treated With Pristane", <u>J. Immunol.</u> 129:2826-2830 (1982)                                       |
| 129                 | Gabizon et al., "Pharmacokinetics and Tissue Distribution of Doxorubicin Encapsulated in Stable Liposomes With Long Circulation Times" <u>J. National Cancer Inst.</u> , 81(19): 1484 (1989)     |
| 130                 | Gelmini et al., "Quantitative polymerase chain reaction-based homogeneous assay with fluorogenic probes to measure c-erbB-2 oncogene amplification" <u>Clin. Chem.</u> 43:752 (1997)             |
| 131                 | Gething et al., "Cell-surface expression of influenza haemagglutinin from a cloned DNA copy of the RNA gene" <u>Nature</u> , 293:620-625 (1981)  |
| 132                 | Glennie and Johnson, "Clinical trials of antibody therapy" <u>Immunol Today</u> 21: 403-410 (2000)   |
| 133                 | Goeddel et al., "Direct expression in <i>Escherichia coli</i> of a DNA sequence coding for human growth hormone" <u>Nature</u> , 281:544 (1979)  |
| 134                 | Goeddel et al., "Synthesis of human fibroblast by <i>E. coli</i> " <u>Nucleic Acids Res.</u> , 8:4057 (1980)   |
| 135                 | Graham et al. "Characteristics of a Human Cell Line Transformed by DNA from human Adenovirus Type 5", <u>J. Gen Virol.</u> , 36:59 (1977)  |

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
GENENT.83AAPPLICATION NO.  
09/901,812INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Pennica et alFILING DATE  
July 10, 2001GROUP  
1645EXAMINER  
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

- |     |   |
|-----|---|
| 136 | Gray et al. "Fluorescence in Situ Hybridization in Cancer and Radiation Biology", <u>Radiation Res.</u> , 137:275-289 (1994)  |
| 137 | Gruber et al "Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Express in Escherichia coli", <u>J. Immunol.</u> 152:5368 (1994)  |
| 138 | He et al., "Identification of c-MYC as a Target of the APC Pathway" <u>Science</u> 281:1509-1512 (1998)   |
| 139 | Hess et al., "Cooperation of Glycolytic Enzymes", <u>J. Adv. Enzyme Reg.</u> , 7:149 (1968)   |
| 140 | Hitzeman et al., "Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by Immunological Screening Technique" <u>J. Biol. Chem.</u> , 255:2073 (1980)   |
| 141 | Hodgson, John, "Data-Directed Drug Design" <u>Bio/Technology</u> , 9: 19-21 (1991)  |
| 142 | Holland and Holland, "Isolation and Identification of yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase and Phosphoglucerate Kinase" <u>Biochemistry</u> , 17:4900-4907 (1978) |
| 143 | Hollinger et al., "Diabodies": Small bivalent and bispecific antibody fragments" <u>Proc. Natl. Acad. Sci. USA</u> , 90:6444-6448 (1993)  |
| 144 | Hongo et al. "Development and Characterization of Murine Monoclonal Antibodies to the Latency-Associated Peptide of Transforming Growth Factor $\beta$ ", <u>Hybridoma</u> 14:253-260 (1995)                                |
| 145 | Hopp et al., "A short polypeptide marker sequence useful for recombinant protein identification and purification" <u>BioTechnology</u> , 6:1204-1210 (1988)   |
| 146 | Hora et al., "Controlled Release of Interleukin-2 From Biodegradable Microspheres", <u>Bio/Technology</u> , 8:755-758 (1990)  |
| 147 | Hsiao et al., "High-frequency transformation of yeast by plasmids containing the cloned yeast ARG4 gene" <u>Proc. Natl. Acad. Sci. (USA)</u> , 76:3829 (1979)   |
| 148 | Huguet et al., "Differential Expression of Human Wnt Genes 2,3,4, and 7B in Human Breast Cell Lines and Normal and disease States of Human Breast Tissue" <u>Cancer Res</u> 54:2615-2521 (1994)                             |
| 149 | Hunter, Tony, "Cooperation between Oncogenes" <u>Cell</u> , 64:1129 (1991)  |
| 150 | Hwang et al. "Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: A kinetic study", <u>Proc. Natl. Acad. Sci. USA</u> , 77: 4030 (1980)  |
| 151 | Hynes and Stern, "The biology of erbB-2/neu/HER-2 and its role in cancer" <u>Biochim. Biophys. Acta</u> , 1198:165-184 (1994)   |
| 152 | Ikegawa et al., "Isolation, characterization and chromosomal assignment of the human WNT7A gene" <u>Cytogenet Cell Genet</u> 74:149-152 (1996)  |
| 153 | Johnson et al., "A month-long effect from a single injection of microencapsulated human growth hormone" <u>Nat. Med.</u> 2:795-799 (1996)   |
| 154 | Jones et al., <u>Nature</u> , "Replacing the complementary-determining regions in a human antibody with those from a mouse" 321:522-525 (1986)  |
| 155 | Jones, Elizabeth W., "Proteinase Mutants of <i>Caccharomyces Cerevisiae</i> " <u>Genetics</u> , 85:12 (1977)  |
| 156 | Kantor et al., "Modulation of Carcinoembryonic Antigen Messenger RNA Levels in Human Colon Carcinoma Cells by Recombinant Human $\gamma$ -Interferon" <u>Cancer Research</u> , 49(1):2651-5 (1989)                          |

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
GENENT.83AAPPLICATION NO.  
09/901,812INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT  
Pennica et alFILING DATE  
July 10, 2001GROUP  
1645

(USE SEVERAL SHEETS IF NECESSARY)

EXAMINER  
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

- 157 Karmali et al., "Prostaglandins in breast cancer: Relationship to disease stage and hormone status" Br. J. Cancer, 48:689-696 (1983)
- 158 Katoh et al., "Cloning expression and chromosomal localization of Wnt-13, a novel member of the Wnt gene family" Oncogene 13:873-876 (1996)
- 159 Kelly and Hynes, "Transformation of *Aspergillus niger* by the amdS gene of *Aspergillus nidulans*" EMBO J., 4:475-479 (1985)
- 160 Keown et al., "Methods for Introducing DNA into Mammalian Cells" Methods in Enzymology, 185:527-537 (1990)
- 161 Kikuchi et al., "The nucleotide sequence of the promoter and the amino-terminal region of alkaline phosphatase structural gene (phoA) of *Escherichia coli*" Nucleic Acids Res. 9:5671-5678 (1981)
- 162 Kim et al., "Anti4-1BB Monoclonal Antibodies Enhance Antitumor Efficacy of Adoptive Immunotherapy Using Tumor-Draining Lymph Node Cells" Proc. Am. Assoc. Cancer Res. 41, 91 Meet., 290, 2000 (Conference abstract: 91<sup>st</sup> Annual Meeting of the American Association for Cancer research, San Francisco, California, USA, 2001)
- 163 Kingsman et al. "Replication In *Saccharomyces cerevisiae* of Plasmid Pbr313 Carrying DNA from the Yeast trp1 Region", Gene, 7:141 (1979)
- 164 Kobayashi et al., "Mutations of the  $\beta$ -Catenin Gene in Endometrial Carcinomas" Jpn. J. Cancer Res. 90:55-9 (1999)
- 165 Koesters et al., "Mutational Activation of the  $\beta$ -Catening Proto-Oncogene Is a Common Event in the Development of Wilms' Tumors" Cancer Res. 59:3880-2 (1999)
- 166 Koj et al. "Regulation of Synthesis of Some Proteinase Inhibitors in Human Hepatome Cells HepG2 by Cytokines, Hepatocyte Growth Factor" Biol Chem Hoppe Seyler 374:193-201 (1993)
- 167 Komine et al. "Genomic Organization and Physical Mapping of the Transfer RNA Genes in *Escherichia coli* K12", J. Mol. Biol. 212:579-598 (1990)
- 168 Korinek et al., "Two members of the Rcf family implicated in Wnt/ $\beta$ -Catenin signaling during Embryogenesis in the Mouse" Mol. Cell Biol. 18:1248-56 (1998)
- 169 Korinek et al., "Constitutive Transcriptional Activation by a  $\beta$ -Catenin-Tcf Complex in APC-/- Colon Carcinoma" Science 275:1784-1787 (1997)
- 170 Kostelny et al., "Formation of a Bispecific Antibody by the Use of Leucine Zippers", J. Immunol. 148(5):1547-1553 (1992)
- 171 Lako et al., "Isolation, characterization and embryonic expression of WNT11, a gene which maps the 11q13.5 and has possible roles in the development of skeleton, kidney and lung" Gene 219:101-110 (1998)
- 172 Lako et al., "Isolation and Characterization of WNT8B, a Novel Human Wnt Gene That Maps to 10q24" Genomics 35:386-388 (1996)
- 173 Lasko et al., "Targeted oncogene activation by site-specific recombination in transgenic mice" Proc. Natl. Acad. Sci. USA, 89:6232-636 (1992)
- 174 Lassam et al., "Synthesis of DNA, Late Polypeptides, and Infectious Virus by Host-Range Mutants of Aenovirus 5 in Nonpermissive Cells" Virology, 87:63-467 (1978)
- 175 Lavitrano et al., "Sperm Cells as vectors for Introducing Foreign DNA into Eggs: Genetic Transformation of Mice" Cell, 57:717-73 (1989)
- 176 Lee et al., "Complexes formed by (pyrimidine)<sub>n</sub>(purine)<sub>n</sub> DNAs on lowering the pH are three-stranded" Nucl. Acids Res., 6:3073 (1979)

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
GENENT.83AAPPLICATION NO.  
09/901,812INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Pennica et alFILING DATE  
July 10, 2001GROUP  
1645EXAMINER  
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

- |     |  |
|-----|--|
| 177 | Lee et al., "Cloning, Chromosomal Localization, and Tissue Expression of Autotaxin from human Teratocarcinoma Cells" <u>Biochem Biophys Res Commun</u> 218:714-719 (1996)  |
| 178 | Li et al., "Targeted Mutation of the DNA Methyltransferase Gene Results in Embryonic Lethality" <u>Cell</u> , 69:915 (1992)  |
| 179 | Lo, Cecilia W., "Transformation by Iontophoretic Microinjection of DNA: Multiple Integration Without Tandem insertions" <u>Mol. Cell Biol.</u> , 3:1803-1814 (1983)  |
| 180 | Lonberg and Huszar, "Human Antibodies from transgenic Mice" <u>Intern. Rev. Immunol.</u> 13 65-93 (1995)   |
| 181 | Lonberg et al., "Antigen-specific human antibodies from mice comprising four distinct genetic modifications" <u>Nature</u> 368 856-859 (1994)  |
| 182 | Louvencourt et al., "Transformation of Kluyveromyces lactis by Killer Plasmid DNA", <u>J. Bacteriol.</u> , 154(2): 737-1742 (1983)   |
| 183 | Lucas et al., "High-Level production of recombinant proteins in CHO cells using a dicistronic DHFR intron expression vector" <u>Nucl. Acids Res.</u> 24(9 ):1774-1779 (1996)   |
| 184 | Lutz-Freyermuth et al., "Quantitative determination that one of two potential RNA-binding domains of the A protein component of the U1 small nuclear ribonucleoprotein complex binds with high affinity to stem-loop II OF U1 RNA" <u>Proc. Natl. Acad. Sci. USA</u> , 87:6393-6397 (1990) |
| 185 | Mansour et al., "Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes" <u>Nature</u> , 336:348-352 (1988)   |
| 186 | Mantei et al., "Rabbit $\beta$ -globin mRNA production in mouse L cells transformed with clone rabbit $\beta$ -globin chromosomal DNA" <u>Nature</u> , 281:40-46 (1979)  |
| 187 | Marasco et al. "Design, intracellular expression, and activity of a human anti-human Immunodeficiency virus type 1 gp120- single-chain antibody, <u>Proc. Natl. Acad. Sci. USA</u> , 90: 7889-7893 (1993)  |
| 188 | Marks et al., "By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage" <u>J. Mol. Biol.</u> , 222:581 (1991)  |
| 189 | Martin and Papahadjopoulos, "Irreversible Coupling of Immunoglobulin Fragments to Preformed Vesicles" <u>J. Biol. Chem.</u> , 257: 286-288 (1982)  |
| 190 | Martin et al., "GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K <sup>+</sup> Channel Current" <u>Science</u> , 255:192-194 (1992)  |
| 191 | Martin-Satue, M. and Blanco, J., "Identification of Semaphorin E Gene Expression in Metastatic Human Lung Adenocarcinoma Cells by mRNA Differential Display" <u>J Surg Oncol</u> 72:18-23 (1999)   |
| 192 | Massey, "Catalytic antibodies catching on" <u>Nature</u> , 328:457-458 (1987)  |
| 193 | Mather, Jennie P. "Establishment and Characterization of two Distinct Mouse Testicular Epithelial Cell Lines", <u>Biol. Reprod.</u> , 23:243-251 (1980)  |
| 194 | McGrew et al., "Direct regulation of the Xenopus engrailed-2 promoter by the Wnt signaling pathway, and a molecular screen for Wnt-responsive genes, confirm a role for Wnt signaling during neural patterning in Xenopus" <u>Mech. Dev.</u> 87:21-32 (1999)                               |
| 195 | McWhirter et al., "Oncogenic homeodomain transcription factor E2A-Pbx1 activates a novel WNT gene in pre-B acute lymphoblastoid leukemia" <u>Proc Natl Acad Sci USA</u> 96:11464-11469 (1999)  |
| 196 | Merrifield, R.B., "Solid Phase Peptide Synthesis. I. The Synthesis of Tetrapeptide" <u>J. Am. Chem. Soc.</u> , 85:2149-2154 (1963)   |

EXAMINER


DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
GENENT.83AAPPLICATION NO.  
09/901,812INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Pennica et alFILING DATE  
July 10, 2001GROUP  
1645EXAMINER  
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

- |     |   |
|-----|---|
| 197 | Miller and Moon, "Signal transduction through $\beta$ -catenin and specification of cell fate during embryogenesis" <u>Genes &amp; Dev.</u> 10:2527-2539 (1996)   |
| 198 | Milstein and Cuello, "Hybrid hybridomas and their use in immunohistochemistry" <u>Nature</u> , 305:537-539 (1983)   |
| 199 | Molenaar, et al., " XTcf-3 Transcription Factor Mediates $\beta$ -Catenin-Induced Axis Formation in Xenopus Embryos" <u>Cell</u> 86:391-399 (1996)  |
| 200 | Mordenti, J. and Chappell, W. "The use of interspecies scaling in toxicokinetics" <u>In Toxicokinetics and New Drug Development</u> , Yacobi et al., Eds., Pergamon Press, New York 1989, pp. 42-96     |
| 201 | Morin et al., "Activation of $\beta$ -Catenin-Tcf Signaling in Colon Cancer by Mutations in $\beta$ -Catenin or APC" <u>Science</u> 275:1787-1790 (1997)  |
| 202 | Morrison, Sherrie L., "Success in specification" <u>Nature</u> 368, 812-13 (1994)   |
| 203 | Moss, "Nomenclature of Retinoids" <u>Biochemical Nomenclature and Related Documents</u> , 2 <sup>nd</sup> edition, Portland Press, 1992, pp 247 -51   |
| 204 | Moss, "Nomenclature of Retinoids" <u>Pure Appl. Chem.</u> , 55:721-726 (1983)   |
| 205 | Moss, "Nomenclature of Retinoids" <u>Eur. J. Biochem.</u> , 129:1-5 (1982)  |
| 206 | Moss, "Nomenclature of Retinoids" <u>J. Biol. Chem.</u> , 258:5329-5333 (1983)  |
| 207 | Moss, G.P., "Nomenclature of Retinoids" <u>Arch. Biochem. Biophys.</u> , 224:728-731 (1983)   |
| 208 | Murata et al., " cDNA Cloning of the Human Tumor Motility-stimulating Protein, Autotaxin, Reveals a Homology with Phosphodiesterases" <u>J Biol Chem</u> 269:30479-84 (1994)                            |
| 209 | Nagasawa et al., "Cloning of the cDNA for a New Member of the Immunoglobulin Superfamily (ISLR) Containing Leucine-Rich Repeat (LRR)" <u>Genomics</u> 44:273-279 (1997)                                 |
| 210 | Nagasawa et al., "Human and Mouse ISLR (Immunoglobulin Superfamily) Containing Leucine-Rich Repeat) Genes: Genomic Structure and Tissue Expression" <u>Genomics</u> 61:37-43 (1999)                     |
| 211 | Nam et al., "Autotaxin 9ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells" <u>Oncogene</u> 19:241-247 (2000)  |
| 212 | Neuberger et al., "Recombinant antibodies possessing novel effector functions" <u>Nature</u> , 312:604-608 (1984)   |
| 213 | Neuberger, Michael, "Generating high-avidity human Mabs in mice" <u>Nature Biotechnology</u> 14, 826 (1996)   |
| 214 | Nusse and Varmus, "Many Tumors Induced by the Mouse Mammary Tumor Virus Contain a Provirus Integrated in the Same Region of the Host Genome" <u>Cell</u> 31:99-109 (1982)                               |
| 215 | Nygren, Hakan "Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents" <u>J. Histochem. and Cytochem.</u> , 30:407 (1982) |
| 216 | Paborsky et al., "Mammalian cell transient expression of tissue factor for the production of antigen" <u>Protein Engineering</u> , 3(6):547-553 (1990)  |
| 217 | Pain an Surolia "Preparation of Protein A-Peroxisase Monoconjugate using a Heterobifunctional Reagent, and its use in Enzyme Immunoassays" <u>J. Immunol. Meth.</u> , 40:219 (1981)                     |
| 218 | Palacios and Hamallo, "Mutations in the $\beta$ -Catenin Gene(CTNNB1) in Endometrioid Ovarian Carcinomas" <u>Cancer Res</u> 58:1344-7 (1998)  |

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.83A	APPLICATION NO. 09/901,812
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Pennica et al	
		FILING DATE July 10, 2001	GROUP 1645



OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
219	Palladino et al. "Characterization of the Antitumor Activities of Human Tumor Necrosis Factor- $\alpha$ and the Comparison with other Cytokines: Induction of Tumor-Specific Immunity", <u>J. Immunol.</u> , 138:4023-4032 (1987)
220	Pearson, D. and Sasse, J., "Differential Regulation of Biglycan and Decorin by Retinoic Acid in Bovine Chondrocytes" <u>J Biol Chem</u> 267:25364-25370 (1992)
221	Peifer and Polakis, "Wnt Signaling in Oncogenesis and Embryogenesis- A Look Outside the Nucleus" <u>Science</u> 287:1606-1609 (2000)
222	Pennica et al., "WISP genes are members of the connective tissue growth factor family that are up-regulated in Wnt-1-transformed cells and aberrantly expressed in human colon tumors" <u>Proc. Natl. Acad. Sci USA</u> 95:14717-22 (1998)
223	Perry, M.C., Ed., <u>Chemotherapy Source Book</u> , Williams & Wilkins, Baltimore, MD (1992)
224	Polakis, Paul, "Wnt signaling and cancer" <u>Genes Dev</u> 14:1837-1851 (2000)
225	Polakis, Paul, "The oncogenic activation of $\beta$ -catenin" <u>Curr. Opin. Genet. Dev.</u> 9:15-21 (1999)
226	Presta, Leonard G., "Antibody engineering" <u>Curr. Op. Struct. Biol.</u> , 2:593-596 (1992)
227	Prete et al., "Drug-Induced Changes of Carcinoembryonic Antigen Expression in Human Cancer Cells: Effect of 5-Fluorouracil" <u>Journal of Pharmacology and Experimental Therapeutics</u> 279(3):1574-81 (1996)
228	Rankin et al., "Partial cloning and assignment of WNT6 to human chromosome band 2q35 by in situ hybridization" <u>Cytogenet Cell Genet</u> 84:50-52 (1999)
229	Ravdin and Chamness, "The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers-a review" <u>Gene</u> , 159:19-27 (1995)
230	Reichmann et al., "Reshaping human antibodies for therapy" <u>Nature</u> , 332:323-329 (1988)
231	Rimm et al., "Frequent Nuclear/Cytoplasmic Localization of $\beta$ -Catenin without Exon 3 Mutations in Malignant Melanoma" <u>Am. J. Pathol.</u> 154:325-9 (1999)
232	Rochette-Egly et al., "The AF-1 and AF-2 Activating Domains of Retinoic Acid Receptor- $\alpha$ (RAR- $\alpha$ ) and Their Phosphorylation Are Differentially Involved in Parietal Endodermal Differentiation of F9 Cells and Retinoid-Induced Expression of Target Genes" <u>Mol. Endocrinol.</u> 14(9):1398-1410 (2000)
233	Roelink et al., "Molecular Cloning and Chromosomal Localization to 17q21 of the Human WNT3 Gene" <u>Genomics</u> 17:790-792 (1993)
234	Roose et al., "Synergy Between Tumor Suppressor APC and the $\beta$ -Catenin-Tcf4 target Tcf1" <u>Science</u> 285:1923-1926 (1999)
235	Rossi, John J., "Making ribozymes work in cells" <u>Current Biology</u> , 4:469-471 (1994)
236	Rubinfeld et al., "Association of the APC Gene Product with $\beta$ -Catenin" <u>Science</u> 262:1731-1734 (1993)
237	Rubinfeld et al., "Association of the APC Gene Product with $\beta$ -Catenin" <u>Science</u> 262:1731-1734 (1993)
238	Rubinfeld et al., "Stabilization of $\beta$ -Catenin by Genetic Defects in Melanoma Cell Lines" <u>Science</u> 275:1790-1792 (1997)
239	Ruppert et al., "Cloning and expression of human TAD..250" a TBP-associated factor implicated in cell-cycle regulation" <u>Nature</u> , 362:175-179 (1993)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
GENENT.83AAPPLICATION NO.  
09/901,812INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Pennica et alFILING DATE  
July 10, 2001GROUP  
1645

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

- |     |   |
|-----|---|
| 240 | Sakanaka, et al., "New steps in the Wnt/beta-catenin signal transduction pathway" "Recent Prog Horm Res 55:225-36 (2000)  |
| 241 | Sambrook et al., <u>Molecular Cloning: A Laboratory Manual</u> (New York: Cold Spring Harbor Laboratory Press, 1989)  |
| 242 | Scholtissek and Grosse, "A cloning cartridge of $\lambda$ t0 terminator" <u>Nucleic Acids Res.</u> 15:3185 (1987)   |
| 243 | Schwab et al. "Amplification of Cellular Oncogenes: A Predictor of Clinical outcome in Human Cancer", <u>Genes Chromosomes Cancer</u> , 1:181-193 (1990)  |
| 244 | Scopes, Robert K., <u>Protein Purification: Principles and Practice</u> , Springer-Verlag, New York (1982)  |
| 245 | Scott et al., "Randomized trial of addition of lamivudine or lamivudine plus zidovudine to zidovudine-containing regimens for patients with HIV-1 infection: the CEASER trial" <u>The Lancet</u> , 349(9063) pS119(4) (May 17, 1997)  |
| 246 | Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene" <u>J. Exp. Med.</u> 175:217-225 (1992)   |
| 247 | Shopes, Bob, "A Genetically Engineered Human IgG Mutant With Enhanced Cytolytic Activity" <u>J. Immunol.</u> , 148: 2918:2922 (1992)  |
| 248 | Slamon et al., "Human Breast Cancer" Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" <u>Science</u> , 235:177-182 (1987)  |
| 249 | Small et al., "Analysis of a Transgenic Mouse Containing Simian Virus 40 and v-myc Sequences" <u>Mol. Cell. Biol.</u> , 5:642-648 (1985)  |
| 250 | Sojar and Bahl, et al., "A Chemical Method for the Deglycosylation of Proteins", <u>Arch. Biochem. Biophys.</u> , 259:52-57(1987)   |
| 251 | Somparyrac et al., "Efficient infection of monkey cells with DNA of simian virus 40" <u>Proc. Natl. Acad. Sci.</u> , 12:7575 (1981)   |
| 252 | Sreekrishna et al., "High level expression of heterologous proteins in methylotrophic yeast <i>Pichia pastoris</i> " <u>J. Basic Microbiol.</u> , 28:265-278 (1988)   |
| 253 | Stella et al., "Prodrugs: A Chemical Approach to Targeted Drug Delivery", University of Kansas and Interx Research Corp., Lawrence, Kansas 66045  |
| 254 | Stevenson et al. "A chimeric antibody with dual Fc regions (bisFaFc) prepared by manipulations at the IgG hinge", <u>Anti-Cancer Drug Design</u> , 3: 219-230 (1989)  |
| 255 | Stewart et al., "An STS-Based Radiation Hybrid Map of the Human Genome" <u>Genome Research</u> , 7:422-433 (1997)   |
| 256 | Stewart et al., <u>Solid-Phase Peptide Synthesis</u> , W.H. Freeman Co., San Francisco, CA (1969)   |
| 257 | Stinchcomb et al., "Isolation and characterization of yeast chromosomal replicator" <u>Nature</u> , 282:39 (1979)   |
| 258 | Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid Hybridomas" <u>Methods in Enzymology</u> , 121:210 (1986)  |
| 259 | Szeto et al., "Overexpression of the Retinoic Acid-Responsive Gene Stra6 Human Cancers and Its Synergistic Induction by Wnt-1 and Retinoic Acid" <u>Cancer Research</u> 61:4197-4250 (May 15, 2001)   |
| 260 | Taneja et al., "Reexpression of retinoic acid receptor (RAR) $\gamma$ or overexpression of RAR $\alpha$ or RAR $\beta$ in RAR $\gamma$ -null F9 cells reveals a partial functional redundancy between the three RAR types" <u>Proc. Natl. Acad. Sci. USA</u> 92:7854-8 (1995) |

EXAMINER


DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
GENENT.83AAPPLICATION NO.  
09/901,812INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Pennica et alFILING DATE  
July 10, 2001GROUP  
1645

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)


EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
261	Tetsu and McCormick, "β-Catenin regulates expression of cyclin D1 in colon carcinoma cells" <u>Nature</u> 398:422-426 (1999)
262	Thimmappaya et al., "Adenovirus VAI RNA Is Required for Efficient Translation of Viral mRNAs at Late Times after infection" <u>Cell</u> , 31:543 (1982)
263	Thomas and Capecchi, "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells" <u>Cell</u> , 51:503 (1987)
264	Thomas, Patricia S., "Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose" <u>Proc. Natl. Acad. Sci. USA</u> , 77:5201-5205 (1980)
265	Thompson et al., "Germ Line Transmission and Expression of a Corrected HPRT Gene Produced by Gene Targeting in Embryonic Stem Cells" <u>Cell</u> , 56:313-321 (1989)
266	Thotakura and Bahl, "Enzymatic Deglycosylation of Glycoproteins" <u>Meth. Enzymol.</u> , 138:350 (1987)
267	Tilburn et al. "Transformation by Integration in <i>Aspergillus nidulans</i> ", <u>Gene</u> , 26:205-221 (1983)
268	Trautnecker et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells" <u>EMBO J.</u> , 10:3655-3659 (1991)
269	Tremblay et al., "Retinoic Acid Stimulates the Expression of 11β-Hydroxysteroid Dehydrogenase Type 2 in Human Choriocarcinoma JEG-3 Cells" <u>Biol Reprod</u> 60:541-545 (1999)
270	Tschumper et al., "Sequence of a yeast DNA fragment containing a chromosomal replicator and the TRP1 gene" <u>Gene</u> , 10:157 (1980)
271	Tsukamoto et al., "Expression of the int-1 Gene in Transgenic Mice Is Associated with Mammary Gland Hyperplasia and Adenocarcinomas in Male and Female Mice" <u>Cell</u> 55:619-625 (1988)
272	Urlaub and Chasin, "Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity" <u>Proc. Natl. Acad. Sci. USA</u> , 77:4216 (1980)
273	Van der Krol et al., "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences" <u>BioTechniques</u> 6:958 (1988)
274	Van der Putten et al., "Efficient insertion of genes into the mouse germ line via retroviral vectors" <u>Proc. Natl. Acad. Sci. USA</u> , 82:6148-615 (1985)
275	Van Ooyen et al., "The nucleotide sequence of the human int-1 mammary oncogene; evolutionary conservation of coding and non-coding sequences" <u>EMBO J</u> 4:2905-9 (1985)
276	Van Solingen et al., "Fusion of Yeast Spheroplasts" <u>J. Bact.</u> , 130:946 (1977)
277	Verhoeven et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> , 239:1534-1536 (1988)
278	Vitetta et al., "Redesigning Nature's Poisons to Create Anti-Tumor Reagents" <u>Science</u> , 238: 1098 (1987)
279	Wade, D. P. and Owen, J. S., "Regulation of the cholesterol efflux gene, ABCA1" <u>Lancet</u> 357:161-163 (2001)
280	Wagner et al., "Transferrin-polycation conjugates as carriers for DNA uptake into cells" <u>Proc. Natl. Acad. Sci. USA</u> 87, 3410-3414 (1990)
281	Wainwright et al., "Isolation of a human gene with protein sequence similarity to human and murine int-1 and the <i>Drosophila</i> segment polarity mutant wingless" <u>EMBO J</u> 7:1743-1748 (1988)

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.83A	APPLICATION NO. 09/901,812
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Pennica et al	
		FILING DATE July 10, 2001	GROUP 1645



EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
282	Warzocha and Wotowiec, "Antisense strategy" biological utility and prospects in the treatment of hematological malignancies." <u>Leuk. Lymphoma</u> 24:267-281 (1997)
283	Wells et al., "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin" <u>Philos. Trans. R. Soc. London SerA</u> , 317:415-423 (1986)
284	Wells et al., "Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites" <u>Gene</u> , 34:315 (1985)
285	Willert et al., "Wnt-induced dephosphorylation of Axin releases $\beta$ -catenin from the Axin complex" <u>Genes Dev.</u> 13:1768-73 (1999)
286	Wilman, Derry E., "Prodrugs in Cancer Chemotherapy", <u>Biochemical Society Transactions</u> , 14:375-382, 615th Meeting, Belfast (1986)
287	Wodarz and Nusse, "Mechanisms of WNT Signaling in Development" <u>Annu Rev Cell Dev Biol</u> 14:59-88 (1998)
288	Wodicka et al., "Genome-wide expression monitoring in <i>Saccharomyces cerevisiae</i> ", <u>Nat Biotechnol</u> 15:1359-1367 (1997)
289	Wong et al. "Differential Transformation of Mammary Epithelial Cells by Wnt Genes" <u>Mol Cell Biol</u> 14:6278-6286 (1994)
290	Wright et al., " $\beta$ -Catenin mutation and expression analysis on ovarian cancer: Exon 3 mutations and nuclear translocation in 16% of endometrioid tumours" <u>Int. J. Cancer</u> 82:625-9 (1999)
291	Wu et al., "Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System" <u>J. Biol. Chem.</u> 262, 4429-4432 (1987)
292	Xiang et al., "Expression of Co-stimulatory 4-1BB Ligand Induces Significant Tumor Regression and Protective Immunity" <u>Cancer Biotherapy and Radiopharmaceuticals</u> , 14(5):353-361 (1999)
293	Yamada et al. "Identification of semaphorin E as non-MDR drug resistance gene of human cancers" <u>Proc Natl Acad Sci U S A</u> 94: 14713-14718 (1997)
294	Yelton et al., "Transformation of <i>Aspergillus nidulans</i> by using trpCplasmid" <u>Proc. Natl. Acad. Sci. USA</u> , 81: 1470-1474 (1984)
295	Zacharski, Leo R., "Basis for Selection of Anticoagulant Drugs for Therapeutic Trials in Human Malignancy" <u>Haemostasis</u> , 16:300-320 (1986)
296	Zamecnik et al., "Inhibition of replication and expression of human T-cell lymphotropic virus type IRII in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA" <u>Proc. Natl. Acad. Sci. USA</u> 83:4143-4146 (1986)
297	Zapata et al., "Engineering linear F(ab') <sub>2</sub> fragments for efficient production in <i>Escherichia coli</i> and enhanced antiproliferative activity" <u>Protein Eng.</u> , 8(10):1057-1062 (1995)
298	Zhang et al., "The Retinoic Acid and cAMP-dependent Up-regulation of 3-O-Sulfotransferase-1 Leads to a Dramatic Augmentation of Anticoagulant Active Heparan Sulfate Biosynthesis in F9 Embryonal Carcinoma Cells" <u>J Biol Chem</u> 273:27998-28003 (1998)
299	Zhang et al., "Gene Expression Profiles in Normal and Cancer Cells" <u>Science</u> 276:1268-1272 (1997)
300	Ziemer et al., "Identification of a Mouse Homolog of the Human BTEB2 Transcription Factor as a $\beta$ -Catenin-Independent Wnt-1 Responsive Gene" <u>Mol Cell Biol</u> 21:562-574 (2001)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
GENENT.83AAPPLICATION NO.  
09/901,812INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Pennica et alFILING DATE  
July 10, 2001GROUP  
1645EXAMINER  
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

301 Zola, Heddy , Monoclonal Antibodies: A Manual of Techniques, CRC Press, Inc. (1987) pp. 147-158302 Zupi et al. "Cloning in Vitro and in Vivo of Lewis Lung Carcinoma: Properties and Characteristics", Br. J. Cancer, 41:suppl. 4:309 (1980)

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.